Income statement, balance sheet and cash flow statement for the last 4 fiscal years, taken from the XBRL data Silence Therapeutics plc files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2022
FY2024
FY2024
FY2025
Revenue
21.7
31.6
43.3
0.56
Cost of revenue
13.5
12.9
11.8
0.22
Gross profit
8.19
18.8
31.4
0.34
Research and development
43.6
56.9
67.9
67.8
General and administrative
25.7
26.2
26.9
22.3
Operating income
-61
-64.4
-63.3
-91.1
Pre-tax income
-49.6
-53.3
-44.5
-88.6
Income tax
0.69
0.96
0.85
0.01
Net income
-50.3
-54.2
-45.3
-88.6
EBITDA
-60.7
-64
-63
-90.8
EPS, basic
-0.52
-0.49
-0.33
-0.63
EPS, diluted
-0.52
-0.49
-0.33
-0.63
Shares, basic (weighted)
96.6
111
139
142
Shares, diluted (weighted)
96.6
111
139
142
Balance sheet
FY2022
FY2024
FY2024
FY2025
Cash and equivalents
68.8
121
11.3
Short-term investments
26
73.8
Receivables
0.29
0.97
0
Other current assets
11.6
14.7
11.5
Total current assets
103
187
119
Property, plant and equipment
1.94
1.82
1.58
Lease right-of-use assets
0.37
0.16
0.17
Goodwill
9.68
9.98
9.39
10.6
Intangible assets
0.31
0.29
Other non-current assets
3.65
3.59
0.13
Total assets
119
203
131
Accounts payable
3.35
3.7
4.41
Deferred revenue
6.57
0.31
0.17
Total current liabilities
22.3
16.8
13.6
Lease liabilities
0.12
0
0.07
Total liabilities
97.5
68.6
69.1
Paid-in capital
456
610
618
Retained earnings
-432
-474
-563
Other comprehensive income
-10.7
-11.8
-2.98
Shareholders' equity
27.2
22
134
62.3
Total equity
27.2
22
134
62.3
Total liabilities and equity
119
203
131
Shares outstanding
108
119
142
142
Cash flow statement
FY2022
FY2024
FY2024
FY2025
Net income
-50.3
-54.2
-45.3
-88.6
Depreciation and amortization
0.38
0.37
0.34
0.31
Stock-based compensation
12.7
16.3
16.3
8.07
Deferred income tax
0.69
0.96
0.85
0.01
Change in receivables
-0.72
0.39
-0.9
1.02
Cash from operations
-57
-49.5
-67.6
-62.3
Capital expenditures
-0.17
-0.06
-0.21
-0.06
Cash from investing
-20.5
19.3
-22
-48
Stock issued
52.6
31.9
142
0.02
Cash from financing
52.6
31.9
142
0.02
Exchange rate effect
-8.12
0.75
0.06
0.2
Net change in cash
-25
1.77
52.5
-110
Free cash flow
-57.2
-49.5
-67.9
-62.3
Income taxes paid
-0.8
0.43
0.64
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $11.20 on September 28, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
85.9%
Gross profit / revenue.
Operating margin
-11,107.0%
Operating income / revenue.
EBITDA margin
-11,058.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-9,748.0%
Pre-tax income / revenue.
Net margin
-9,748.0%
Net income / revenue.
FCF margin
-6,873.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-6,872.0%
Cash from operations / revenue.
Return on equity (ROE)
-155.8%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-56.3%
Net income / average total assets.
R&D / revenue
7,734.0%
Research and development expense / revenue.
Stock-based pay / revenue
1,009.0%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.5%
Capital expenditures / revenue.
D&A / revenue
49.3%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-98.7%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-70.4%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit growth, 1y
-98.9%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
-65.2%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y
-53.5%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
31.8%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
-35.1%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
2.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
13.6%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
7.42x
Current assets / current liabilities.
Quick ratio
5.67x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
5.67x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.00
Revenue / diluted weighted shares.
FCF per share
-$0.30
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.30
Cash from operations / diluted weighted shares.
Book value per share
$0.27
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
852x
Market cap / revenue.
P/B
13.6x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
18.6x
Market cap / tangible book value, when positive.
EV/Sales
735x
Enterprise value / revenue.
FCF yield
-8.1%
Free cash flow / market cap.
Earnings yield
-11.4%
Net income / market cap (the inverse of P/E).
What was Silence Therapeutics plc's revenue in fiscal 2025?
Silence Therapeutics plc reported revenue of $559.0K for fiscal 2025, 98.7% lower than the year before.
Was Silence Therapeutics plc profitable in fiscal 2025?
No. It reported a net loss of $88.6M.
How much free cash flow did Silence Therapeutics plc generate in fiscal 2025?
Cash from operations of $62.3M minus capital expenditures of $55.0K left free cash flow of -$62.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.